PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates

PD-1/PD-L1 Control of Antigen-Specifically Activated CD4 T-Cells of Neonates

Newborns are highly susceptible to infections; however, the underlying mechanisms that regulate the anti-microbial T-helper cells shortly after birth remain incompletely understood. To address neonatal antigen-specific human T-cell responses against bacteria, <i>Staphylococcus aureus</i>...

Full description

Bibliographic Details
Main Authors:	Christiane Majer, Holger Lingel, Aditya Arra, Hans-Gert Heuft, Dirk Bretschneider, Silke Balk, Katrin Vogel, Monika C. Brunner-Weinzierl
Format:	Article
Language:	English
Published:	MDPI AG 2023-03-01
Series:	International Journal of Molecular Sciences
Subjects:	T-helper cells CD4 T cell immune checkpoint molecule PD-1/PD-L1 <i>Staphylococcus aureus</i> (<i>S. aureus</i>) bacteria
Online Access:	https://www.mdpi.com/1422-0067/24/6/5662

Similar Items

The changes in peripheral blood Th17 and Treg ratios in Hashimoto’s thyroiditis are accompanied by differential PD-1/PD-L1 expression
by: Jun Fang, et al.
Published: (2022-08-01)

Analysis of CXCL9, PD1 and PD-L1 mRNA in Stage T1 Non-Muscle Invasive Bladder Cancer and Their Association with Prognosis
by: Jennifer Kubon, et al.
Published: (2020-09-01)

Association between <i>PD-1</i> and <i>PD-L1</i> Polymorphisms and the Risk of Cancer: A Meta-Analysis of Case-Control Studies
by: Mohammad Hashemi, et al.
Published: (2019-08-01)

Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?
by: Andrea Toledo, et al.
Published: (2023-09-01)

Large cell morphology, CMYC+ tumour cells, and PD-1+ tumour cell/intense PD-L1+ cell reactions are important prognostic factors in nodal peripheral T-cell lymphomas with T follicular helper markers
by: Yasuhito Mihashi, et al.
Published: (2021-11-01)

Pharmacokinetics and Pharmacodynamics (PK/PD) of Corallopyronin A against Methicillin-Resistant <i>Staphylococcus aureus</i>
by: Katharina Rox, et al.
Published: (2022-12-01)

<i>PD-1</i> and <i>PD-L1</i> Expression Levels as a Potential Biomarker of Chronic Rhinosinusitis and Head and Neck Cancers
by: Katarzyna Malinowska, et al.
Published: (2023-03-01)

Noncanonical PD-1/PD-L1 Axis in Relation to the Efficacy of Anti-PD Therapy
by: Yiru Long, et al.
Published: (2022-05-01)

PD-1/PD-L1 Checkpoint Inhibitors Are Active in the Chicken Embryo Model and Show Antitumor Efficacy <i>In Ovo</i>
by: Yan Wang, et al.
Published: (2022-06-01)

Role of regulation of PD-1 and PD-L1 expression in sepsis
by: Teng Zhang, et al.
Published: (2023-03-01)

Effect of Rapamycin on Exosomes and PD-1/PD-L1 in Human Erythroleukemia HEL Cells
by: QI Lin, et al.
Published: (2022-10-01)

Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade
by: Oliver Kepp, et al.
Published: (2019-10-01)

PD-1/PD-L1 in Cancer: Pathophysiological, Diagnostic and Therapeutic Aspects
by: Enrico Munari, et al.
Published: (2021-05-01)

Promises and Pitfalls in the Use of PD-1/PD-L1 Inhibitors in Multiple Myeloma
by: Stefania Oliva, et al.
Published: (2018-11-01)

PD-1 limits differentiation and plasticity of Tc17 cells
by: Aditya Arra, et al.
Published: (2023-04-01)

Determination of PD-L1 Expression in Circulating Tumor Cells of NSCLC Patients and Correlation with Response to PD-1/PD-L1 Inhibitors
by: Melanie Janning, et al.
Published: (2019-06-01)

The PD1: PD-L1/2 pathway from discovery to clinical implementation
by: Kankana Bardhan, et al.
Published: (2016-12-01)

Differential Engraftment of Parental A20 PD-L1 WT and PD-L1 KO Leukemia Cells in Semiallogeneic Recipients in the Context of PD-L1/PD-1 Interaction and NK Cell-Mediated Hybrid Resistance
by: Maria-Luisa del Rio, et al.
Published: (2022-06-01)

PD-1/PD-L1 Pathway: A Therapeutic Target in CD30+ Large Cell Lymphomas
by: Wei Xie, et al.
Published: (2022-07-01)

A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy
by: Yuanyuan Wang, et al.
Published: (2021-05-01)

Combination Approaches to Target PD-1 Signaling in Cancer
by: Emily K. Moore, et al.
Published: (2022-07-01)

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation
by: Mengling Wu, et al.
Published: (2022-03-01)

PD-1 gene polymorphisms and thyroid expression of PD-1 ligands differ between Graves’ and Hashimoto’s diseases
by: Mayumi Kawabata, et al.
Published: (2021-10-01)

Sequence Analysis and Functional Verification of the Effects of Three Key Structural Genes, <i>PdTHC2’GT</i>, <i>PdCHS</i> and <i>PdCHI</i>, on the Isosalipurposide Synthesis Pathway in <i>Paeonia delavayi</i> var. <i>lutea</i>
by: Hongzhu Zou, et al.
Published: (2022-05-01)

Abrogation of IFN-γ Signaling May not Worsen Sensitivity to PD-1/PD-L1 Blockade
by: Julie Vackova, et al.
Published: (2020-03-01)

Augmented Antitumor Effect of Unripe <i>Rubus coreanus</i> Miquel Combined with Oxaliplatin in a Humanized PD-1/PD-L1 Knock-In Colorectal Cancer Mouse Model
by: Eun-Ji Lee, et al.
Published: (2022-09-01)

Blocking the PD-1/PD-L1 axis enhanced cisplatin chemotherapy in osteosarcoma in vitro and in vivo
by: Xiaoqiang Liu, et al.
Published: (2019-12-01)

Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab
by: Nicolas A. Giraldo, et al.
Published: (2018-10-01)

The significance of PD-1/PD-L1 imbalance in ulcerative colitis
by: Wei Shi, et al.
Published: (2023-05-01)

Integrated molecular and immunophenotypic analysis of NK cells in anti-PD-1 treated metastatic melanoma patients
by: Hansol Lee, et al.
Published: (2019-02-01)

PD−L1 immunostaining: what pathologists need to know
by: Mohammed Akhtar, et al.
Published: (2021-10-01)

The Role of PD-1 in Acute and Chronic Infection
by: Jil M. Jubel, et al.
Published: (2020-03-01)

Research Progress of PD-1/PD-L1 Checkpoint Inhibitors in (Neo) Adjuvant Therapy for Malignant Melanoma
by: ZOU Hanhui, et al.
Published: (2020-02-01)

Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature
by: Francesco Sabbatino, et al.
Published: (2018-11-01)

A Higher Dose of <i>Staphylococcus aureus</i> Enterotoxin B Led to More Th1 and Lower Th2/Th1 Ratio in Th Cells
by: Jin Yuan, et al.
Published: (2023-05-01)

The PD-1/PD-L1 Axis in the Biology of MASLD
by: Rosaria Maria Pipitone, et al.
Published: (2024-03-01)

BICD Cargo Adaptor 1 (BICD1) Downregulation Correlates with a Decreased Level of PD-L1 and Predicts a Favorable Prognosis in Patients with IDH1-Mutant Lower-Grade Gliomas
by: Shang-Pen Huang, et al.
Published: (2021-07-01)

Combination therapy with PD-1/PD-L1 blockade: An overview of ongoing clinical trials
by: C. Bryce Johnson, et al.
Published: (2018-04-01)

Meta-analysis of the correlation between glioma prognosis and PD-1/PD-L1 expression
by: Chang-cheng Ren, et al.
Published: (2023-12-01)

PD-1/PD-L1 axis in organ fibrosis
by: Youliang Zhao, et al.
Published: (2023-05-01)